Ironwood Pharmaceuticals Reports $300M Adjusted EBITDA Guidance
Ironwood Pharmaceuticals (NASDAQ:IRWD) on Feb. 25 announced fiscal 2026 adjusted EBITDA guidance of at least $300 million and reaffirmed its 2026 outlook, citing improving LINZESS dynamics. On Feb. 26 Citizens analyst Jason Butler maintained an Outperform rating and raised the price target to $10. The company plans Phase 3 STARS-2 site initiations in Q2 and continues development of apraglutide for SBS-IF.
Scoring Rationale
Same-day company guidance and analyst confirmation provide credible, actionable investor information. Score reflects moderate novelty and company-level scope, strong credibility from official guidance, but limited broader industry impact and non-technical relevance.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problemsStep-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Sources
- Read Original5 Best Small-Cap Drug Manufacturing Stocks to Buy According to Hedge Fundsinsidermonkey.com
